Back to top
more

Integra LifeSciences (IART)

(Real Time Quote from BATS)

$29.12 USD

29.12
195,950

+0.27 (0.94%)

Updated Jun 14, 2024 11:04 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 249)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cerner (CERN) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Cerner's (CERN) second-quarter results are likely to reflect solid show by Subscriptions, Managed Services and Licensed software segments.

DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) second-quarter results are likely to reflect rising global awareness of its real-time CGM.

Quidel (QDEL) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Quidel (QDEL) is likely to have witnessed an uptick in rapid immunoassay revenues in Q2.

Deferred Procedures to Mar Boston Scientific (BSX) Q2 Earnings

by Zacks Equity Research

With lockdowns continuing through all three months of the second quarter, Boston Scientific (BSX) is expected to have faced a more dreadful time.

PerkinElmer (PKI) to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

PerkinElmer's (PKI) second-quarter results are likely to reflect strong performance at Diagnostics segment. However, forex remained a woe.

ViewRay (VRAY) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Strength in MRIdian system business is likely to have aided ViewRay's (VRAY) performance in second-quarter 2020 amid the coronavirus-led economic doldrums.

Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) Global Industrial segment is likely to have gained from the Water, Food & Beverage and Life Sciences sub-units in Q2.

Can Diagnostics Aid Hologic (HOLX) Q3 Earnings Amid Coronavirus?

by Zacks Equity Research

Strength in segmental business is likely to have aided Hologic's (HOLX) performance in third-quarter fiscal 2020 amid the coronavirus-led economic doldrums.

Growing Testing Capacity to Aid LabCorp's (LH) Q2 Earnings?

by Zacks Equity Research

LabCorp's (LH) developments to support COVID-19 testing are believed to have contributed to the company's second-quarter earnings.

Testing Volume to Aid Quest Diagnostics' (DGX) Q2 Earnings?

by Zacks Equity Research

Looking at this demand for testing, Quest Diagnostics (DGX) has significantly picked up capacity to perform molecular diagnostic tests a day.

What's in Store for West Pharmaceutical's (WST) Q2 Earnings?

by Zacks Equity Research

West Pharmaceutical Services (WST) is likely to have gained from continued strength in high-value product sales in Q2.

What's in the Cards for Intuitive Surgical (ISRG) Q2 Earnings?

by Zacks Equity Research

Intuitive Surgical's (ISRG) second-quarter earnings are likely to reflect weaker-than-expected performance at Instruments & Accessories segment and decline in da Vince procedure volume.

What's in Store for Edwards Lifesciences (EW) in Q2 Earnings?

by Zacks Equity Research

Robust customer adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve are likely to have driven Edwards Lifesciences' (EW) Q2 revenues.

Align Technology (ALGN) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Align Technology (ALGN) is expected to have gained from continued strength in Clear Aligner shipment volumes in Q2.

Thermo Fisher (TMO) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

The rest of businesses within Life-Science Solutions segment of Thermo Fisher (TMO) are likely to have registered strong quarterly growth led by genetic sciences and bio production businesses.

Integra Reports Organic Sales Drop in Preliminary Q2 Results

by Zacks Equity Research

Integra (IART) projects a severe impact on revenues due to the coronavirus-led economic crisis despite sequential improvement in monthly sales performance throughout the quarter.

Urmimala Biswas headshot

Medical Instruments Outlook Dull Amid Coronavirus Crisis

by Urmimala Biswas

Many sub domains within the medical instrument space are bearing the brunt of the coronavirus-led prolonged stay-at-home orders.

Integra (IART) Up 8.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Integra (IART) Lags Q1 Earnings Estimates, Withdraws Outlook

by Zacks Equity Research

Integra's (IART) first-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.

Integra LifeSciences (IART) Misses Q1 Earnings Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of -20.00% and 0.46%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Integra LifeSciences (IART) Reports Next Week: What to Know Ahead of the Release

by Zacks Equity Research

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain HealthEquity Stock for Now

by Zacks Equity Research

Investor confidence remains high in HealthEquity (HQY) stock, thanks to solid prospects.

Bio-Rad Launches Serology Test to Detect Coronavirus Antibody

by Zacks Equity Research

Bio-Rad (BIO) launches a blood-based immunoassay kit to better detect antibodies in response to SARS-CoV-2 infection.

Why Integra (IART) Could Beat Earnings Estimates Again

by Zacks Equity Research

Integra (IART) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Integra Releases Preliminary Q1 Results, Withdraws '20 View

by Zacks Equity Research

Integra (IART) unable to measure the magnitude of total loss it has to bear out of the coronavirus-led economic damages, and hence, withdraws the full-year guidance.